Use of &bgr;-lactamase inhibitors as neuroprotectants

Details Use of &bgr;-lactamase inhibitors as neuroprotectants Use of &bgr;-lactamase inhibitors as neuroprotectants

2001-02-13

2002-07-30

Jarvis, William R. A. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S192000, C514S193000, C514S210100

Reexamination Certificate

active

06426342

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to a new use of inhibitors of bacterial &bgr;-lactamases. More particularly, this invention is directed to the use of &bgr;-lactamase inhibitors for preventing or reducing neuronal damage in patients suffering from or susceptible to disease states characterized by loss of neuronal cells or loss of neuronal cell function.
BACKGROUND OF THE INVENTION
Over excitation of NMDA receptor channel complexes on post-synaptic neurons following excessive release of glutamic acid from synaptozones and glial cells results in massive calcium ion influx into neuronal cells leading to their death. This is believed to occur under conditions such as stroke, hypoglycemia, cardiac arrest, and other hypoxic or ischemic processes, including, for example, neural trauma, and perinatal asphyxia. Other conditions known to result in or from loss of neuronal cells or loss of neuronal function include seizure activity such as that associated with epilepsy, amyliotrophic lateral sclerosis (ALS), Alzheimer's disease, Huntington's disease, Parkinsonism and dementia such as multi-infarct dementia, vascular dementia, and neurodegenerative dementia. Other conditions known to result in loss of neuronal cells or loss of neuronal cell function are those generally characterized as secondary neurodegenerative disease of typically metabolic or toxic origin. While significant progress has been made in developing therapeutics for treatment or prevention of such neurodegenerative conditions or disease states, there still exists significant need for the development of alternative therapies for treatment of patients afflicted with such conditions.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a surprisingly effective neuroprotective therapy. It is based on the discovery that compound capable of inhibiting the activity of bacterial &bgr;-lactamases (i.e., &bgr;-lactamase inhibitors) is, as well, a powerful neuroprotective agent. The invention thus provides a method for preventing neuronal damage or the progression of neuronal damage in a patient suffering from or susceptible to said damage, characterized generally as a loss of neuronal cells or a loss of neuronal cell function, such as that secondary to the occurrence of strokes, seizures, neural trauma, and a multiplicity of neuro-degenerative disease states of widely variant etiology.
In another embodiment of the invention there is provided a neuroprotective pharmaceutical composition and a method for manufacturing same using a &bgr;-lactamase inhibitor as the active ingredient. Such pharmaceutical compositions can be formulated in unit dosage forms adapted for patient delivery by a wide variety of routes of administration including, but not limited to, oral ingestion, buccal, sublingual, parenteral, transdermal and rectal routes of administration. In one embodiment the dosage forms are formulated for controlled release of the &bgr;-lactamase inhibitor.


REFERENCES:
patent: 4268503 (1981-05-01), Imanaka et al.
patent: 4302447 (1981-11-01), Horrobin
patent: 4594247 (1986-06-01), Brier
patent: 5763603 (1998-06-01), Trickes
patent: 5795877 (1998-08-01), Jackson et al.
patent: 5824662 (1998-10-01), Slusher et al.
patent: 5863536 (1999-01-01), Jackson et al.
patent: 5880112 (1999-03-01), Jackson et al.
patent: 5905076 (1999-05-01), Singh et al.
patent: 5912242 (1999-06-01), Pevarello et al.
patent: 5968915 (1999-10-01), Jackson et al.
patent: 5977090 (1999-11-01), Slusher et al.
patent: 6004946 (1999-12-01), Slusher et al.
patent: 6015809 (2000-01-01), Zhu et al.
patent: 6017903 (2000-01-01), Slusher et al.
patent: 1 508 977 (1979-04-01), None
patent: WO 95/20980 (1995-08-01), None
patent: WO 97/10247 (1997-03-01), None
“The Relation Between Fear Induced by Novel Stimulation and Exploratory Behavior” by K.C. Montogomery J. Comp. Physiol. Psychol. (1955) vol. 48, 254-260.
“Action of Penicillin on Inhibitory Processes in the Cat's Cortex” by H.V. Duijn, P.A. Schwartzkroin, and D.A. Prince, Brain Res. (1973) vol. 53, 470-476.
“Convulsant Actions of Penicillin: Effects on Inhibitory Mechanisms” by H. Meyer and D. Prince (1973) vol. 53, 477-482.
“Penicillin Decreases Chloride Conductance in Crustacean Muscle: A Model for the Epileptic Neuron” by B. Hochner, M.E., Spira, and R. Werman. Brain Res. (1976) vol. 107, 85-103.
A.B. Chernomordik. Klin. Med. (1980) vol. 2. 102-105.
“Antagonism by Penicillin of Gamma-Aminobutyric Acid Depolarizations at Presynaptic Sites in Rat Olfactory Cortex and Cuneate Nucleus In Vitro” by H.G. Pickles and M.A. Simmonds, Neuropharmacology (1980) vol. 19, 35-38.
“GABA and the Behavioral Effects of Anxiolytic Drugs” D.J. Sanger, Life Sciences (1985) vol. 36, 1503-1513.
“Convulsant Doses of Penicillin Shorten the Lifetime of GABA-Induced Channels in Cultured Central Neurones” by P. Chow and D. Mathers, Br. J. Pharmac. (1986) vol. 88. 541-547.
“N-methyl-D-aspartate Receptors and the Enhancement of Somatosensory Evoked Potentials in Penicillin Epileptogenesis in Rats” by Z.J. Bashir and O. Holmes, Physiological Society (1987) 19P.
“Competitive Inhibition of N-Acetylated-alpha-Linked Acidic Dipeptidase Activity by N-Acetyl-L-Aspartyl-beta-Linked L-Glutamate” by V. Serval. L. Barbeito, A. Piltaluga, A. Cheramy, S. Lavielle, and J. Glowinski, J. Neurochemistry (1990) vol. 55, 39-46.
“Time Course of Interictal EEG Patterns Induced by a Penicillin Injection into the Olfactory Cortex” by E. Horn, K. Esseling, and R. Wagner, Pharmacology Biochemistry & Behavior (1991) vol. 40, 351-357.
“The Pharmacology of Recombinant GABA, Receptors Containing Bovine alphal. betal, gamma2L Sub-units Stably Transfected into Mouse Fibroblast L-cells” by A.L. Home, K.L. Hadingham, A.J. Macaulay, P. Whiting and J.A. Kemp, Br. J, Pharmacology (1992) vol. 107, 732-737.
I.V. Batueva N.P. Vesclkin, and R. Veskov, Neirofiziologiya (1992) vol. 24, (2), 151-160.
“Increased Intra-and Extracellular Concentrations of Gamma-Glutamylglutamate and Related Dipeprides in the Ischemic Rat Striatum: Involvement of Gamma-Glutamyl Transpeptidase” by O. Orwar, X. Li, P. Andine, C.M. Bergström, H. Hagberg, S. Folestad, and M. Sandberg, J. Neurochemistry (1994) vol. 63, 1371-1376.
“Endogenous Gamma-L-Glutamyl and Beta-L-Asparty) Peptides and Excitatory Aminoacidergic Neurotransmission in the Brain” by V. Varga, R. Janaky, P. Saransaari, and S.S. Oja. Neuropeptides (1994) vol. 27, 19-26.
“Penicllins and Their Derivatives: Antiulcer/Antistress Properties?” by A. V. Kalueff, G.E. Samonina, and I.P. Ashmarin, Neuropschychopharmacology (1994) vol. 10, 272S.
“Behavioral Effects of Penicillin in a Test for Anxiety in Rats” by A. V. Kaluev, G.E. Samonina and I.P. Ashmarin. Bulletin of Experimental Biology and Medicine (1995) vol. 120, 984-986.
“Design, Synthesis , and Biological Activity of a Potent Inhibitor of the Neuropeptides N-Acetylated Alpha-Linked Acidic Dipeptidase” by P.F. Jackson, D.C. Cole, B.S. Slushes, S. Stetz, L.E. Ross, B.A. Donzanti, and D.A. Trainor, J. Med. Chem. (1996) vol. 39(2), 619-622.
“Gamma-L-Glutamyl-L-Aspartate Induces Specific Deficits in Long-Term Memory and Inhibits [3H] Glutamate Binding on Hippocampel Membranes” by A. Ungerer, M.S. Bourgeois, C. Mélan, Y. Boulanger, J. Reinbolt, I. Amiri, and J.D. Barry, Brain Res. (1988) vol. 446, 205-211.
nE.F. Reynolds, “Martindale, The Extra Pharmocopoeia, ”Royal Pharmaceutical Society, London, p. 211, Column 2-3, (1996) XP-00216510.
Passani, Lucius A., “N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases,”Molecular and Chemical Neuropathology, vol. 31, No. 2, pp. 97-118, (1997) XP-000987254.
Macknin, M.L., “Behavioral changes after amoxicillin-clavulanate,” letter,Pediatric Infectious Disease Journal, vol. 6, No. 9, (Sep. 1987) XP-000987254.
Tsai, Guochuan, et al., “Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains”,Archives of General Psychiatry, vol. 52, No. 10, pp. 829-636, (1995) XP-00987256.
Pangalos,

Affiliated with

Also associated with

Rating

Use of &bgr;-lactamase inhibitors as neuroprotectants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of &bgr;-lactamase inhibitors as neuroprotectants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of &bgr;-lactamase inhibitors as neuroprotectants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2879645